Natural solutions for diabetes: the therapeutic potential of plants and mushrooms
Aleksandra Sknepnek1, Dunja Miletić1, Alena Stupar2
1Faculty of Agriculture, Institute of Food Technology and Biochemistry, University of Belgrade, Belgrade, Serbia.
Abstract:
Medicinal plants and mushrooms have been used for the prevention and treatment of various diseases since ancient times. For thousands of years, they have attracted significant interest due to their broad spectrum of biological activities and drug-like properties. Their continued use in traditional medicine has evolved alongside, and increasingly been supported by modern scientific research. Diabetes mellitus poses a serious global health, social and economic challenge and is among the most rapidly growing health issues of the 21st century. Type 2 diabetes mellitus (T2DM), which accounts for 90-95% of diabetes cases, is largely attributed to sedentary lifestyles, unhealthy diets and obesity. Herbal medicine has already played a key role in the development of antidiabetic drugs, as exemplified by the plant-derived origins of metformin. The development of new therapeutics or therapeutic adjuvants from natural sources offers several advantages over synthetic drugs, including improved safety profiles for long-term use, efficacy, affordability and reliance on renewable raw materials. This review highlights the potential of bioactive compounds from medicinal plants and mushrooms, discussing their mechanism of action, extraction techniques and their significance for the prevention, management and treatment of T2DM.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Mesenchymal Stem Cells
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...


